Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
29 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté
5 publications sur 5 ans↗
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
6
6 articles ont été cités au moins 6fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
223
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
10
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
5
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Le Havre Normandie
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
2025ArticleThe Lancet
The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
2024ArticleLa Revue de Médecine Interne
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study
2023ArticleThe Lancet Rheumatology
Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort
2022ArticleBritish Journal of Haematology
Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction
2019ArticlePLoS ONE
Development of a thrombin generation test in cultured endothelial cells: Evaluation of the prothrombotic effects of antiphospholipid antibodies
2018ArticleThrombosis Research
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL JACQUES MONOD CH LE HAVRE
29 R P MENDES FRANCE, 76290 MONTIVILLIERS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Lupus · 2016
Cyclophosphamide (CYC) is used in severe neuropsychiatric systemic lupus erythematosus (NPSLE), but long-term data regarding its efficacy and safety are lacking. We identified NPSLE cases who received CYC from two centres during the period 1999–2013 and had regular follow-up. General and neuropsychiatric outcome at last follow-up visit were determined, and major complications were documented. CYC was administered in 50 neuropsychiatric events. Median age was 45.0 years and 46% of patients were positive for antiphospholipid antibodies. Most frequent indications were psychosis (11 cases), polyneuropathy (six cases), and cerebrovascular disease, seizure disorder and cranial neuropathy (five cases). CYC was mainly administered as monthly pulses (median number: 8.0 (range 3–26), median cumulative dose: 7.2 g (range 2.4–33.8)). Cases were followed for a median of 46.5 months (range 5–408). At last follow-up, partial or complete response of NPSLE was observed in 84% of events; 10% had stable disease, whereas the remaining 6% failed to improve or worsened and were rescued with rituximab. In events that responded to CYC, maintenance therapy consisted of azathioprine in 31 events (65.9%), bimonthly or quarterly pulses of intravenous CYC in nine (19.1%), and mycophenolate mofetil in five (10.6%). Relapses were observed in six events (12%) at median eight months after initial response. No malignancies were observed, yet there were three cases of severe infections. Amenorrhea was recorded in three patients, who had not received gonadal protection. In conclusion, cyclophosphamide was efficacious and led to sustained response of severe NPSLE in a cohort with long follow-up.
Rheumatology (Oxford, England) · 2015
Abstract Objective To compare the European League Against Rheumatism (EULAR) recommendations for the management of NPSLE with usual care in two tertiary centres and to detect potential pitfalls in their use for diagnosis and treatment. Methods A chart-based review of NPSLE manifestations was conducted in two European centres. Diagnostic and treatment decisions were compared against the EULAR recommendations for general NPSLE and specific manifestations. Results We studied a total of 94 patients who experienced 123 lupus-related neuropsychiatric events over 10 years. In 80% of the events, at least one EULAR-defined risk factor (previous NPSLE, generalized disease activity or aPL positivity) was present. Overall, there was good concordance between clinical care and recommendations for diagnosis and treatment (68.7% and 62.7% of events, respectively). Brain MRI was performed in the absence of a clear EULAR recommendation in 42.9% of events; therein, it was more frequently normal compared with imaging performed according to the recommendations (52.4% vs 18.5%, P = 0.008), and it did not influence management. Among patients reporting cognitive dysfunction, only 27.8% underwent the recommended neuropsychological assessment. In line with the recommendations, immunosuppressants were more frequently given in events suggestive of an inflammatory process (80.5% vs 47.6% in non-inflammatory events, P < 0.001). Notably, 52% of cerebrovascular events were managed with combined immunosuppressive/antithrombotic therapy due to either coexisting generalized lupus activity or recurrence despite prior antithrombotic treatment. Conclusion Despite good concordance between EULAR recommendations for NPSLE and usual clinical practice, we identified a number of issues (such as overutilization of brain MRI, suboptimal evaluation of cognitive dysfunction, and frequent use of immunosuppressives in cerebrovascular disease) that need to be investigated further.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Lancet. Rheumatology · 2026 · Journal Article
Andersen J, Talarico R, Marinello D, Aguilera S, et al.
British journal of haematology · 2022 · Journal Article
Maisonobe L, Bertinchamp R, Damian L, Gérard L, et al.
Diagnostics (Basel, Switzerland) · 2020 · Case Reports
Damian L, Lebovici A, Pamfil C, Belizna C, et al.
Medical ultrasonography · 2019 · Case Reports
Damian LO, Simon SP, Felea I, Coman M, et al.
Journal of clinical immunology · 2018 · Case Reports
Damian L, Sauvêtre G, Marguet F, Verdalle-Cazes M, et al.
Medical ultrasonography · 2018 · Journal Article
Vele P, Simon SP, Damian L, Felea I, et al.
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie · 2018 · Case Reports
Damian LO, Manole S, Pamfil CAM, Rogojan L, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016 · Case Reports
Damian LO, Simon SP, Filipescu I, Bocsa C, et al.
The American journal of emergency medicine · 2016 · Case Reports
Damian LO, Lenuţ C, Dîrzu DS, Cristea A, et al.
Medical ultrasonography · 2015 · Comparative Study
Ghib LJ, Tămaş MM, Damian LO, Felea I, et al.
Medical ultrasonography · 2013 · Case Reports
Damian LO, Felea I, Boloşiu C, Botar-Jid C, et al.
American journal of otolaryngology · 2013 · Case Reports
Maniu A, Damian L
Diagnostics (Basel, Switzerland) · 2026 · Case Reports
Sparchez M, Damian L, Socaciu MA, Fufezan O, et al.
Expert review of hematology · 2025 · Journal Article
Damian L, Langlois V, Jardin F, Kerleau JM, et al.
Journal of clinical medicine · 2024 · Journal Article
Popescu I, Pintican R, Cocarla L, Burger B, et al.
Autoimmunity reviews · 2018 · Journal Article
Belizna C, Stojanovich L, Cohen-Tervaert JW, Fassot C, et al.
Lupus · 2016 · Journal Article
Fanouriakis A, Pamfil C, Sidiropoulos P, Damian L, et al.
Rheumatology (Oxford, England) · 2015 · Comparative Study
PloS one · 2019 · Journal Article
Miranda S, Billoir P, Damian L, Thiebaut PA, et al.
Thrombosis research · 2018 · Journal Article
Billoir P, Miranda S, Damian L, Richard V, et al.
Autoimmunity reviews · 2018 · Journal Article
Diagnostics (Basel, Switzerland) · 2026 · Journal Article
Iojiban M, Stanciu BI, Damian L, Lenghel LM, et al.
Journal of neurology · 2020 · Journal Article
Pindi Sala T, Villedieu M, Damian L, Crave JC, et al.
Rheumatology international · 2020 · Journal Article
Bădărînză M, Serban O, Maghear L, Bocsa C, et al.
International journal of molecular sciences · 2023 · Journal Article
Manole S, Rancea R, Vulturar R, Simon SP, et al.
Journal of personalized medicine · 2021 · Case Reports
Moroșan D, Șerban A, Trifan C, Encica S, et al.
Medicine · 2021 · Case Reports
Worbe N, Damian L, Le Cam-Duchez V, Levesque H, et al.
PloS one · 2019 · Journal Article
Miranda S, Billoir P, Damian L, Thiebaut PA, et al.
Pediatric rheumatology online journal · 2015 · Journal Article
Spârchez M, Lupan I, Delean D, Bizo A, et al.
Clinical and experimental rheumatology · 2022 · Journal Article
Petitdemange A, Sztejkowski C, Damian L, Martin T, et al.
Cureus · 2025 · Case Reports
De la Paz FGE, Damian LF
Clinical and experimental rheumatology · 2022 · Journal Article
Petitdemange A, Sztejkowski C, Damian L, Martin T, et al.
Pamfil C, Fanouriakis A, Damian L, Rinzis M, et al.
Belizna C, Stojanovich L, Cohen-Tervaert JW, Fassot C, et al.